Published: Jan 13, 2021
BOSTON, Jan. 13, 2021 /PRNewswire/ NanoView Biosciences, Inc., the leader in single exosome characterization, today announced the expansion of its management team with the appointment of David Hanlon, Ph.D. to the position of Vice President, Strategic Collaborations. The addition is a key part of the company s strategy to create and expand strategic partnerships within the life sciences, pharmaceutical and diagnostics markets.
Dr. Hanlon brings over 20 years of product development and commercialization experience to NanoView, most recently serving as Vice President of Strategic Collaborations at Quanterix. Over the last 12 years he has led the strategic marketing efforts and established an assay service laboratory to support new applications and drive commercial interest. He has held leadership roles in several life sciences and diagnostics companies, including Hologic (formerly Cytyc), where he directed multiple biomarker programs to
NanoView Biosciences and Quantum Design China Enter into Distribution Agreement
News provided by
Share this article
Share this article
BOSTON, Dec. 16, 2020 /PRNewswire/ NanoView Biosciences, Inc., and Quantum Design China, a subsidiary of Quantum Design International, today announced an exclusive distribution agreement for NanoView s ExoView
® platform in China. We are pleased to offer customers in China access to the ExoView platform, which allows scientists the unprecedented ability to accurately identify and characterize extracellular vesicles, including exosomes and viruses said Lamber Cao, General Manager of Quantum Design China. We look forward to working closely with the NanoView team to introduce this unique technology to the rapidly expanding field of nanomedical research.